Business · 07/10/2005

FDA and HHS Solicit Public Review and Comment on Research Protocol for Gonadotropin-releasing Hormone Agonist Test in Disorders of Puberty

The Office for Human Research Protections, Office of Public Health and Science, and the Food and Drug Administration are seeking public input on a proposed research study using Gonadotropin-releasing Hormone (GnRH) Agonist to treat disorders of puberty, to be conducted at the University of Chicago Hospitals General Clinical Research Facility and supported by the National Center for Research Resources of the National Institutes of Health.